# Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report

## TL;DR

A patient with advanced cancer showed improved response to treatment after adding an anti-inflammatory drug that targets IL-6.

## Contribution

This case report demonstrates the potential benefit of combining IL-6 inhibition with anti-PD-1 therapy in cancer treatment.

## Key findings

- The patient's symptoms improved rapidly after tocilizumab treatment.
- Subsequent anti-PD-1 plus chemotherapy led to a favorable response and disease stability.
- Targeting IL-6 may improve therapeutic outcomes in cancer-associated inflammation.

## Abstract

Cancer-related inflammation contributes to the progression of malignancies and considerably affects therapeutic outcomes. IL-6 acts as a main mediator of both local and systemic inflammatory responses. Although IL-6 therapies have been successful in the treatment of inflammatory conditions, there has been little experience in patients with cancer.

A 66-year-old man was diagnosed with gastroesophageal junction squamous cell carcinoma (stage IV) with liver metastasis. The patient presented with notable cancer-associated systemic inflammatory symptoms, and experienced disease progression after initial two cycles of anti-PD-1 combined with chemotherapy. After tocilizumab treatment, the symptoms improved rapidly. The patient showed favorable response to subsequent anti-PD-1 plus second-line chemotherapy, and survived without disease progression.

Targeting IL-6 holds promise for the management of cancer-associated inflammation and improvement of therapeutic outcomes.